Naz News, Gappers and FLE's

[iconoclassic]

ENMD, 2.28, EntreMed announces Pharmacokinetic goals achieved in two clinical trials (ENMD) 2.40 +0.14:Co announces interim results for two Phase Ib studies for its lead clinical-stage drug candidate, Panzem NCD, in patients with advanced cancer. Results from both dose-escalation studies concluded that the pharmacokinetic profile of Panzem NCD met the study objective. Specifically, a dose and schedule of administration was determined that provided constant exposure of 2-methoxyestradiol allowing the selection of a Phase II dose. Results from the University of Wisconsin have determined a maximum tolerated dose with fatigue as the dose limiting toxicity.